Fundraising Fox

Inhibrx

La Jolla, US · Founded 2017 · California corporation · 3 known investors

inhibrx.com ↗

Inhibrx Biosciences, Inc. is a biotechnology company that was spun off as a subsidiary of Inhibrx, Inc. through a pro rata distribution of shares to shareholders. This page is a corporate securities/investor notice describing that organizational action rather than the company's products.

Biotechin /inhibrx@inhibrx

Founders & leadership

ML
Mark LappeExecutive Officer, Director
DF
Doug ForsythDirector
BE
Brendan EckelmanDirector
JL
Judith LiDirector
JF
Jon Faiz KayyemDirector
MF
Margery FischbeinDirector

Investors · 3

LAVHong Kong · $5M – $15M
Lilly Asia VenturesHong Kongvia Hongbo Lu · inferred
RA CapitalBoston

Reported raises · per SEC filings

Form D private placements
▶$200MraisedAug 2023 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark LappeExecutive Officer, Director
  • Kristiina VuoriDirector
  • Kelly DeckExecutive Officer
  • Jon KayyemDirector
  • Brendan EckelmanExecutive Officer
  • Kimberly ManhardDirector
  • Douglas ForsythDirector
Offering amount
$200M
Amount sold
$200M
First sale
Aug 2023
Incorporated
Corporation, California
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedApr 2020 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Judith LiDirector
  • Jon KayyemDirector
  • Kelly DeckExecutive Officer
  • Doug ForsythDirector
  • Brendan EckelmanExecutive Officer, Director
  • Mark LappeExecutive Officer, Director
Offering amount
$30M
Amount sold
$15M
First sale
Apr 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$40MraisedMay 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kelly DeckExecutive Officer
  • Judith LiDirector
  • Doug ForsythDirector
  • Margery FischbeinDirector
  • Jon Faiz KayyemDirector
  • Brendan EckelmanDirector
  • Mark LappeExecutive Officer, Director
Offering amount
$40M
Amount sold
$40M
First sale
May 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedMay 2018 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jon Faiz KayyemDirector
  • Brendan EckelmanDirector
  • Margery FischbeinDirector
  • Judith LiDirector
  • Doug ForsythDirector
  • Mark LappeExecutive Officer, Director
Offering amount
$75M
Amount sold
$3.5M
First sale
May 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$410MraisedMay 2018 · 71 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark LappeExecutive Officer, Director
  • Doug ForsythDirector
  • Brendan EckelmanDirector
  • Judith LiDirector
  • Jon Faiz KayyemDirector
  • Margery FischbeinDirector
Offering amount
$410M
Amount sold
$410M
First sale
Apr 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.